60 Minutes in NASHville

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Non-alcoholic fatty liver disease (NAFLD) occurs when an excess of fat lipids is stored in liver cells; nonalcoholic steatohepatitis (NASH) is an advanced form where tissue inflammation and liver cell damage is underway. The NIH estimates 85 million Americans have NAFLD and over 17 million have NASH. NASH is linked directly to diabetes, obesity and hypertension and bears a substantial unmet medical need.

This session will explore the prevalence of NASH, review the advances in noninvasive diagnostics, examine the recent FDA guidance development programs and dive into the therapeutics marketplace expected to come on line over the next 5 years, all in the vein of ensuring optimal access and reimbursement.